top of page
gradientForSurfBreak.png

Item List

EIN News
xCures and Oblato announce the launch of a Compassionate Use program for OKN-007

xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). Oblato is currently developing OKN-007 as a treatment for glioblastoma multiforme (GBM).

Recent Posts

Portfolio Company

Carlsmed.png

Selfii Announces TripleBlind Exchange, a First-of-its-Kind Marketplace Providing ...

Businesswire

Portfolio Company

Carlsmed.png

Atropos Health and xCures Advance Artificial Intelligence (AI) to Improve Clinic ...

Businesswire

Portfolio Company

Carlsmed.png

DeepScribe and Pearl Health Announce Partnership to Bring Ambient AI Documentati ...

StreetInsider

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page